🔴 Pyxis Oncology is trading 21.34% down in pre-market

Pyxis Oncology is trading 21.34% down at $3.06 in pre-market after closing at $3.89 on September 8, 2026.

• The company scheduled a 7:30 a.m. ET webcast for September 9 to present updated Phase 1 MICVO data in recurrent/metastatic head and neck cancer.
• Thomas Civik was appointed permanent CEO and chairman, effective September 4.
• No reliable source directly attributes the pre-market decline to either announcement.